Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PN-232 · 1 trial · 1 indication
Number and Severity of Adverse Events
| Arm | Type | Description |
|---|---|---|
| Single Dose | EXPERIMENTAL | Single dose administration |
| Multiple Dose | EXPERIMENTAL | Multiple dose administration |
| Solid Dose Comparison | EXPERIMENTAL | Solid dose administration |
| Name | Type | Description |
|---|---|---|
| PN-232 | DRUG | Active Drug |
| Placebo | DRUG | Matching Placebo |
Key Inclusion Criteria: * Subjects must have BMI between 18 and 32 kg/m2 * Subjects must be non-smokers or social smokers * Subjects must comply with contraception requirements * Subjects must be willing to consume meals provided by the clinical center * Subjects must be willing to attend required ...
PN-232 is an investigational small molecule being studied in healthy subjects. It is currently in Phase 1 clinical development, with a completed trial evaluating its pharmacokinetics in healthy volunteers. The drug is not approved for any indication and remains in early-stage clinical testing.
PN-232 is being developed by Protagonist Therapeutics, Inc., a biopharmaceutical company listed on the NASDAQ under the ticker PTGX. The company is conducting clinical research on this investigational small molecule in healthy subjects.
PN-232 is in Phase 1 clinical development. A Phase 1 trial has been completed, and the drug remains investigational. It has not been approved by regulatory authorities and is still undergoing early-stage clinical evaluation in healthy subjects.
PN-232 has one completed clinical trial, identified as NCT04819620, titled "Pharmacokinetics of PN-232 in Healthy Volunteers." This Phase 1 study enrolled 48 healthy subjects in Australia and was a randomized, double-blind, controlled trial.
PN-232 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The only completed trial was a pharmacokinetic study in healthy volunteers, and the drug has not yet progressed to later-stage trials or regulatory approval.